156 related articles for article (PubMed ID: 8339288)
41. A Phase I study of granulocyte-macrophage-colony stimulating factor/interleukin-3 fusion protein (PIXY321) following ifosfamide, carboplatin, and etoposide therapy for children with recurrent or refractory solid tumors: a report of the Children's Cancer Group.
Cairo MS; Krailo MD; Weinthal JA; Secola R; Bergeron S; van de Ven C; Blazar BR; Garrison L; Reaman GH
Cancer; 1998 Oct; 83(7):1449-60. PubMed ID: 9762948
[TBL] [Abstract][Full Text] [Related]
42. Comparative pharmacokinetics of oral and intravenous ifosfamide/mesna/methylene blue therapy.
Aeschlimann C; Küpfer A; Schefer H; Cerny T
Drug Metab Dispos; 1998 Sep; 26(9):883-90. PubMed ID: 9733667
[TBL] [Abstract][Full Text] [Related]
43. [Isolation and characterisation of two main metabolites of ifosfamide from human urine (author's transl)].
Norpoth K; Müller G; Raidt H
Arzneimittelforschung; 1976; 26(7):1376-7. PubMed ID: 1036928
[TBL] [Abstract][Full Text] [Related]
44. Clinical pharmacokinetics of ifosfamide in combination with N-acetylcysteine.
Benvenuto JA; Ayele W; Legha SS; Raber MN; Nicaise C; Newman RA
Anticancer Drugs; 1992 Feb; 3(1):19-23. PubMed ID: 1623211
[TBL] [Abstract][Full Text] [Related]
45. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
Tedeschi A; Montillo M; Strocchi E; Cafro AM; Tresoldi E; Intropido L; Nichelatti M; Marbello L; Baratè C; Camaggi CM; Morra E
Cancer Chemother Pharmacol; 2007 May; 59(6):771-9. PubMed ID: 17256136
[TBL] [Abstract][Full Text] [Related]
46. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
47. Metabolism and pharmacokinetics of oxazaphosphorines.
Boddy AV; Yule SM
Clin Pharmacokinet; 2000 Apr; 38(4):291-304. PubMed ID: 10803453
[TBL] [Abstract][Full Text] [Related]
48. The pharmacokinetics and metabolism of ifosfamide during bolus and infusional administration: a randomized cross-over study.
Singer JM; Hartley JM; Brennan C; Nicholson PW; Souhami RL
Br J Cancer; 1998 Mar; 77(6):978-84. PubMed ID: 9528844
[TBL] [Abstract][Full Text] [Related]
49. Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer.
Willits I; Price L; Parry A; Tilby MJ; Ford D; Cholerton S; Pearson AD; Boddy AV
Br J Cancer; 2005 May; 92(9):1626-35. PubMed ID: 15827549
[TBL] [Abstract][Full Text] [Related]
50. Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy.
Kurowski V; Wagner T
Cancer Chemother Pharmacol; 1993; 33(1):36-42. PubMed ID: 8269587
[TBL] [Abstract][Full Text] [Related]
51. Population pharmacokinetics of ifosfamide and its 2- and 3-dechloroethylated and 4-hydroxylated metabolites in resistant small-cell lung cancer patients.
Kerbusch T; vanPutten JW; Groen HJ; Huitema AD; Mathĵt RA; Beijnen JH
Cancer Chemother Pharmacol; 2001 Jul; 48(1):53-61. PubMed ID: 11488525
[TBL] [Abstract][Full Text] [Related]
52. Ifosfamide--pharmacologic overview.
Sarosy G
Semin Oncol; 1989 Feb; 16(1 Suppl 3):2-8. PubMed ID: 2649983
[TBL] [Abstract][Full Text] [Related]
53. [Solid phase-sample preparation of ifosfamide and chloroethyl metabolites in biological material. 1. Determination in plasma and urine].
Hennig B; Rädler S; Blaschke G; Boos J
Pharmazie; 1992 Oct; 47(10):783-7. PubMed ID: 1480658
[TBL] [Abstract][Full Text] [Related]
54. Ifosfamide pharmacokinetics.
Lewis LD
Invest New Drugs; 1991 Nov; 9(4):305-11. PubMed ID: 1804803
[TBL] [Abstract][Full Text] [Related]
55. Ifosfamide enantiomers: pharmacokinetics in children.
Prasad VK; Corlett SA; Abaasi K; Heney D; Lewis I; Chrystyn H
Cancer Chemother Pharmacol; 1994; 34(5):447-9. PubMed ID: 8070015
[TBL] [Abstract][Full Text] [Related]
56. A study of 5 day fractionated ifosfamide pharmacokinetics in consecutive treatment cycles.
Lewis LD
Br J Clin Pharmacol; 1996 Aug; 42(2):179-86. PubMed ID: 8864315
[TBL] [Abstract][Full Text] [Related]
57. [Metabolism of enantiomers of the cytostatic ifosfamide].
Blaschke G; Widey W
Arzneimittelforschung; 1989 Feb; 39(2):223-6. PubMed ID: 2730691
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM.
Kerbusch T; Huitema AD; Ouwerkerk J; Keizer HJ; Mathôt RA; Schellens JH; Beijnen JH
Br J Clin Pharmacol; 2000 Jun; 49(6):555-61. PubMed ID: 10848719
[TBL] [Abstract][Full Text] [Related]
59. Stereoselective pharmacokinetics of ifosfamide and its 2- and 3-N-dechloroethylated metabolites in female cancer patients.
Granvil CP; Ducharme J; Leyland-Jones B; Trudeau M; Wainer IW
Cancer Chemother Pharmacol; 1996; 37(5):451-6. PubMed ID: 8599868
[TBL] [Abstract][Full Text] [Related]
60. Studies on the metabolism of isopnosphamide (NSC-109724) in man.
Norpoth K
Cancer Treat Rep; 1976 Apr; 60(4):437-43. PubMed ID: 1277219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
